N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

Dardenne, E.; Beltran, H.; Benelli, M.; Gayvert, K.; Berger, A.; Puca, L.; Cyrta, J.; Sboner, A.; Noorzad, Z.; Macdonald, T.; Cheung, C.; Yuen, K. S.; Gao, D.; Chen, Y.; Eilers, M.; Mosquera, J. -M.; Robinson, B. D.; Elemento, O.; Rubin, M. A.; Demichelis, F.; Rickman, D. S.

doi:10.1016/j.ccell.2016.09.005

The transition from castration-resistant prostate adenocarcinoma (CRPC) to neuroendocrine prostate cancer (NEPC) has emerged as an important mechanism of treatment resistance. NEPC is associated with overexpression and gene amplification of MYCN (encoding N-Myc). N-Myc is an established oncogene in several rare pediatric tumors, but its role in prostate cancer progression is not well established. Integrating a genetically engineered mouse model and human prostate cancer transcriptome data, we show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC. This includes an abrogation of androgen receptor signaling and induction of Polycomb Repressive Complex 2 signaling. Altogether, our data establishes N-Myc as an oncogenic driver of NEPC.

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer / Dardenne E.; Beltran H.; Benelli M.; Gayvert K.; Berger A.; Puca L.; Cyrta J.; Sboner A.; Noorzad Z.; MacDonald T.; Cheung C.; Yuen K.S.; Gao D.; Chen Y.; Eilers M.; Mosquera J.-M.; Robinson B.D.; Elemento O.; Rubin M.A.; Demichelis F.; Rickman D.S.. - In: CANCER CELL. - ISSN 1535-6108. - STAMPA. - 30:(2016), pp. 563-577. [10.1016/j.ccell.2016.09.005]